Engineered CH3 Domains for Preferential Bispecific Heterodimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bispecific antibodies face challenges such as inefficient production processes, stability issues, and short half-lives in humans, primarily due to mispairing of heavy and light chains, which complicates the manufacturing of these therapeutic antibodies.
Innovation Solution
The development of variant CH3 domains with specific substitutions, such as T366V and Y407V, that promote preferential heterodimerization through disulfide bonding, allowing for the production of multi-specific antibodies or antigen-binding fragments by incubating parent molecules in reducing and non-reducing environments to form heteromeric molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If co-expression of two heavy chains and two light chains is used to produce bisspecific antibodies, then multiple antigen binding specificities are achieved, but mispairing of chains occurs leading to mixture of sixteen possible combinations
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions (e.g., T366V, Y407V) at defined positions within the CH3 domain to create distinct pairing specificities. These localized modifications enable Heavy Chain 1 to preferentially pair with Heavy Chain 2 while preventing homodimer formation, thereby achieving accurate chain pairing without compromising the multispecific binding capability
Solution Approach 2:
The patent employs asymmetry by creating non-identical CH3 domains through targeted amino acid substitutions. The asymmetric modifications (e.g., T366V in one chain, Y407V in the other) break the symmetry of wild-type CH3 domains, enabling directional and selective heterodimerization while preventing symmetric homodimer formation, thus resolving the mispairing issue
2Adaptability or versatility
If separate production of first and second heavy-light chain pairs followed by mixing is used, then bisspecific antibody formation is achieved, but only 50% maximal yield is obtained due to three possible combinations
Solution Approach 1:
The patent uses local quality modifications in the CH3 domain (specific amino acid substitutions at positions 366 and 407) to create preferential heterodimerization. This ensures that when separate heavy-light chain pairs are mixed, the engineered domains guide correct pairing, achieving near-100% yield of the desired bispecific antibody instead of the theoretical 50% maximum
Solution Approach 2:
The patent applies parameter changes by modifying the amino acid sequence parameters of the CH3 domain. Specific substitutions (T366V, Y407V) alter the physical-chemical properties of the domain interface, creating complementary shapes and interactions that favor heterodimer formation. This parameter modification directly increases production yield by eliminating mispairing
3Manufacturing precision
If common heavy chains with different light chains are used, then mispairing is obviated, but diversity is substantially reduced and specificity of each binding arm is compromised
Solution Approach 1:
The patent resolves this contradiction by applying local quality modifications exclusively to the CH3 domain while leaving the antigen-binding variable regions and other functional domains unchanged. The targeted amino acid substitutions (T366V, Y407V) are confined to the Fc region, ensuring that chain pairing accuracy is improved without affecting the diversity or specificity of the antigen-binding arms
Solution Approach 2:
The patent uses segmentation by separating the function of chain pairing (handled by the modified CH3 domain) from the function of antigen binding (handled by the variable regions). This functional segmentation allows independent optimization: the CH3 domain ensures accurate pairing through engineered heterodimerization, while the variable regions maintain full diversity and specificity for different antigens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the efficiency and specificity of bispecific antibody production by ensuring higher yields of the desired heterodimers, reducing mispairing, and improving stability and half-life in humans.
Implementation Method 1
variant CH3 domains with specific substitutions, such as T366V and Y407V, that promote preferential heterodimerization through disulfide bonding
Data Source
AI summary
Variant CH3 domain polypeptides are provided that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Such variant CH3 domains can be used to promote desired Fc pairing, thus providing for efficient development of bispecific and multispecific antibodies as well as Fc fusions of different formats. Methods of producing bispecific antibodies using such variant CH3 domains and for producing libraries containing such variant CH3 domains are also provided.